Home Top Stories NAFDAC projects 60% GMP compliance among drug manufacturers by 2027

NAFDAC projects 60% GMP compliance among drug manufacturers by 2027

0
25

– As stakeholders call for innovation, quality, collaboration in pharma sector

A cross-section of dignitaries at the opening ceremony of the Ogun State Zone of NAIP Week, held recently.

The National Agency for Food and Drug Administration and Control (NAFDAC) has projected that about 60 per cent of pharmaceutical manufacturing facilities in Nigeria will meet global Good Manufacturing Practice (GMP) standards by this time next year.

The agency also disclosed that drug imports into the country have dropped by more than 70 per cent, from over 450 billion metric tonnes in 2021 to about 100 billion metric tonnes currently, as local pharmaceutical manufacturing continues to expand.

The Director-General of NAFDAC, Prof. Mojisola Adeyeye, disclosed this recently at the opening ceremony of the 2026 week of the Association of Industrial Pharmacists of Nigeria (NAIP), Ogun State Zone, held at Ijoko, Ogun State.

Adeyeye who was represented by the Chief Regulatory Officer and Lead GMP Inspector at NAFDAC, Pharmacist Samson Fatoki, said the significant improvement in GMP compliance is the result of several regulatory reforms and interventions introduced by NAFDAC to strengthen the pharmaceutical manufacturing sector and improve the quality of medicines produced in Nigeria.

Speaking on the theme, “Production Innovation, Quality Standard: Collaboration and Advancement in Technology of Pharmaceutical Industry in Nigeria,” the NAFDAC boss said the agency is encouraged by the progress being made by local manufacturers and is confident that the industry would achieve a much higher level of compliance in the coming year.

She said the number of pharmaceutical manufacturing sites in Nigeria had increased from 165 in 2019 to 184 as of September 2026, while the percentage of manufacturers meeting GMP standards has also risen substantially.

According to her, only about five per cent of manufacturers met GMP standards in 2019, while about 32 per cent were compliant as of March 2026. She added that the figure is gradually approaching 40 per cent based on the latest inspections.

“I can tell you that, based on the figures that we have and what we are seeing during our site inspections, by this time next year, we should be having about 60 per cent of our manufacturers meeting global GMP standards”, she said.

Adeyeye described the anticipated improvement as a major development for the pharmaceutical industry, saying it would further strengthen confidence in medicines manufactured in Nigeria and create opportunities for greater investment in the sector.

She said the progress has already begun to attract foreign direct investment, with foreign companies showing increasing interest in establishing pharmaceutical manufacturing operations or partnering with Nigerian manufacturers.

The NAFDAC DG recalled that the GMP roadmap carried out between 2017 and 2019, with support from UNIDO and the United States, had revealed that more than 85 per cent of pharmaceutical manufacturers in Nigeria were classified as high-risk, while less than five per cent were meeting the required quality standards at the time.

She said NAFDAC subsequently introduced several measures to reverse the situation, including mandatory layout reviews, centralised GMP inspections, risk-based regulatory approaches and increased engagement with manufacturers.

Adeyeye said the agency has reviewed more than 200 pharmaceutical plant layout applications since 2021, covering new facilities as well as existing manufacturers upgrading their plants to comply with World Health Organisation GMP requirements.

She noted that many manufacturers had responded positively by retrofitting old facilities, constructing new plants and investing in modern manufacturing technologies. According to her, the regulatory reforms were also contributing to a gradual reduction in Nigeria’s dependence on imported medicines.

“In 2021, we had more than 450 billion metric tonnes of drugs into the country. As of today, it has dropped to about 100 billion metric tonnes. There has been a drastic reduction. That’s more than 70 per cent”, she said.

She attributed part of the development to the 5+5 regulatory policy, which provides a framework for importers of certain medicines to migrate their products to local manufacturing. Under the policy, she explained, importers are given an initial five-year window and another five years, after which they are expected to establish local manufacturing capacity for the affected products.

Adeyeye said the policy has encouraged several companies previously dependent on imports to establish manufacturing facilities in Nigeria, while local manufacturers have also expanded their capacity.

She also disclosed that NAFDAC has expanded its ceiling list from nine to 36 products, preventing the importation of medicines that Nigerian manufacturers have demonstrated the capacity to produce locally.

As of March 2026, she said, 78 products had shown potential for migration to local manufacturing, adding that the trend is expected to continue as regulatory policies increasingly favour domestic production.

She urged pharmaceutical manufacturers to embrace innovation and technological advancement, warning that the rapidly changing global pharmaceutical environment means that the Nigerian industry cannot afford to remain tied to outdated manufacturing practices.

Adeyeye said developments in artificial intelligence, biotechnology, personalised medicines and advanced therapy medicinal products are changing the global healthcare landscape, stressing that Nigerian manufacturers must position themselves to benefit from the emerging opportunities.

She also highlighted NAFDAC’s efforts to strengthen the pharmaceutical supply chain through technology-driven initiatives such as the Scan to Verify application, NAFDAC Green Book, MedSafety application and Mobile Authentication Service.

According to her, the initiatives would help consumers and healthcare professionals verify medicines and guard against the infiltration of substandard and falsified products into the supply chain.

She further disclosed that NAFDAC is working towards attaining WHO Maturity Level Four and advancing its participation in international regulatory frameworks, including the Pharmaceutical Inspection Co-operation Scheme (PIC/S).  Adeyeye said improved regulatory standards will not only protect public health but also position Nigerian pharmaceutical manufacturers to compete favourably in international markets.

Also speaking, the Father of the Day and Managing Director of Jawa International, Chief Varkey Verghese, called on pharmaceutical manufacturers to make continuous innovation a priority, particularly in product formulation, packaging and production processes.

Verghese said innovation have transformed different sectors globally and should equally drive the pharmaceutical industry in Nigeria. He cited developments in drug formulations and packaging as examples of how innovation could make medicines easier to administer, transport and produce, urging manufacturers to continually explore new technologies and formulations.

He commended Nigeria’s progress in pharmaceutical regulation and expressed optimism that the country’s movement towards WHO Maturity Level Four would further boost confidence in medicines manufactured locally.

He said compliance with regulatory requirements should be regarded as part of the pharmaceutical industry’s ethical responsibility rather than merely a requirement imposed by regulators. “The pharmaceutical industry plays a critical role in safeguarding public health, and maintaining the quality, safety and efficacy of medicines must remain our collective priority”, he said.

He also stressed the importance of pharmacovigilance and post-marketing surveillance, saying continuous monitoring of medicines after regulatory approval is necessary to identify safety concerns and protect patients.

The NAIP National Chairman, Pharm. (Sir) Bankole Ezebuilo who was represented by Pharmacist Emeka Ndineche, commended the Ogun State Zone for its contributions to the development of the association.

He described Ogun NAIP as one of the most reliable branches of the association and urged the state chapter to sustain its achievements while scaling up its activities. He assured the chapter of the national body’s continued support, saying the leadership is encouraged by what the Ogun State zone had achieved.

Earlier in his remarks, the Chairman of NAIP Ogun State Zone, Pharmacist (Mrs.) SerahPearl Kolade, called for greater cooperation among pharmacists, pharmaceutical manufacturers and other stakeholders to strengthen the pharmaceutical industry in the state. Kolade stressed the importance of collaboration, innovation and quality production in addressing the challenges confronting the pharmaceutical sector.

The event featured two plenary sessions involving experts from the pharmaceutical industry. The first plenary, with the topic “Safeguarding Medicines: Advancing Innovation, Compliance and Patient Trust,” was moderated by the Production Head, May & Baker Plc, Pharm. Ariike Mbaneme; while the second plenary, with the topic, “Ensuring Drug Product Safety: Control Strategies from Development to Distribution,” was moderated by Pharm. Emmanuel Ogana, Superintendent Pharmacist at Ranbaxy-Sun Pharma Nigeria Limited.

The association also used the occasion to launch its brand-new bus as part of activities marking the NAIP Ogun State Week.

LEAVE A REPLY

Please enter your comment!
Please enter your name here